Finding. Melittin, the peptide that makes bee venom tear holes in membranes, kills hepatocellular carcinoma cells by a second route. Zang, Guo and colleagues show that Huh7 and Hepa1-6 cells swell, balloon, leak lactate dehydrogenase, and stop cloning. In Hepa1-6, gasdermin E is cleaved to its pore-forming N-terminus. Gasdermin D is not. Mitochondria look wrecked, lose membrane potential, and spill reactive oxygen species. Mito-TEMPO, a mitochondrial oxidant scavenger, cuts those oxidants, eases the pyroptotic membrane damage, and gives some viability back.
Why this paper matters
The textbook says melittin is a detergent with a helical punch. That textbook is not wrong. It is incomplete if part of the plasma-membrane catastrophe is pyroptosis lit by the mitochondrion. GSDME is the gasdermin that turns caspase-3 apoptosis into lysis in many epithelial and tumor cells. Seeing GSDME, not GSDMD, after a “lytic peptide” is the difference between innate-immune pyroptosis and chemotherapy-adjacent secondary necrosis.
The Mito-TEMPO result is the mitochondrial claim. If scavenging organelle oxidants reduces membrane damage, the peptide is not only sanding lipids. It is driving an mtROS-dependent death program that then opens the cell from the inside. Proteomics and ultrastructure are there to show the organelle was a target, not a spectator.
What they did not claim
They call this, to their knowledge, the first evidence that melittin induces pyroptosis in HCC cells through mitochondrial oxidative stress and GSDME processing. They also say the conventional membrane-lytic view is extended, not discarded. That matches a partial rescue. Direct lysis remains on stage.
How to read the score
Upper seventies. Clean mitochondrial executioner story, named gasdermin, scavenger rescue, two HCC lines. Confidence is medium: in vitro, GSDME details highlighted in the murine line, no animal tumor in the abstract. Melittin’s pharmacology is infamous; mechanism papers do not sanitize the peptide.
Caveats
Pyroptotic morphology plus GSDME cleavage is strong but not a full caspase map. Partial Mito-TEMPO rescue means dual mechanisms. Bee venom is not a liver-cancer protocol. Off-tumor lysis is the historical reason this peptide stays in the lab.
What to do with it
If you track mtROS and gasdermin biology, add melittin as a GSDME, not GSDMD, trigger in HCC lines. If you screen mitochondria-targeted antioxidants, this is a positive-control death path. If you write cancer-therapy copy, stop at the mechanism. The translational object is the mtROS/GSDME axis, not a hive.